The goal of this observational study is to compare the real-life effectiveness and safety of vedolizumab, ustekinumab and JAK inhibitors in patients with UC who had been exposed to at least one anti-TNF-alpha therapy.
Established diagnosis of UC according to the current European Crohn's and Colitis Organization (ECCO) guidelines7;
Age ≥ 18 years-old;
Capability of expressing informed consent;
Clinically active ulcerative colitis (cf. 'operative clinical measures', below) at baseline;
Diagnosis of Crohn's colitis, IBD-U or other gastrointestinal inflammatory conditions;
Age < 18 years-old;
Incapability of expressing informed consent;
Acute severe UC requiring hospitalization at baseline;
Patients with ulcerative colitis
Cohort
Retrospective
Vedolizumab
DrugUC patients treated with vedolizumab
Ustekinumab - Standard Dosage
DrugUC patients treated with ustekinumab
JAK Inhibitor
DrugUC patients treated with JAK inhibitors
Clinical and endoscopic effectiveness of the three treatments
Rates of steroid-free clinical remission and endoscopic remission
Map coordinates are unavailable for these locations. Locations are shown below instead.
ItalyClick on the lead sponsor to view all of their trials.
